NARRATIVE – Biotech has this time joined forces with a large laboratory, MSD, to develop this serum against melanoma.
After the Covid, it is now on cancer that Moderna is betting to propel itself among Big Pharma. American biotech has just taken a crucial step in the development of a personalized vaccine against this disease. It has published positive preliminary phase 2 results in the treatment of melanoma, a skin cancer.
“It’s a 2.0 revolution in the fight against cancer, which makes it possible to amplify the effects of immunotherapy, says Stéphane Bancel, CEO of Moderna, at Figaro. We are now showing that our vaccine, combined with the best product available on the market, Keytruda, almost halves the risk of death or relapse compared to Keytruda injected alone. The objective is now to extend the field of this vaccine based on messenger RNA to other indications in cancer. » If the phase 3 studies (the last phase), which should start in 2023, are successful, this vaccine could be marketed at the end of 2025…
This article is for subscribers only. You have 80% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login